EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy

Xingzhou Peng, Wei Chen, Shuyu Li, Xiaomin Ma, Yanfeng Dai, Yan Wang, Changqiang Xie, Yazhe Xiao, Hesong Han, Yumiao Zhang, Junjie Wang

BMEMat · 21.05.2026

DOI: 10.1002/bmm2.70102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMEMat, online erschienen am 21.05.2026. Verfasst von Xingzhou Peng und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer therapeutic efficacy is significantly influenced by tumor immunosuppressive environment possibly induced by chemotherapy‐mediated tumor‐intrinsic programmed death‐ligand 1 (PD‐L1) upregulation or tumor‐associated macrophages (TAMs) promoting additional PD‐L1 expression on tumor cells through distinct paracrine signaling pathways. To overcome this dual resistance mechanism, we developed a hyaluronic acid‐functionalized nanoplatform for co‐delivering DOX and nitric oxide (NO) donor S‐nitroso‐N‐acetylpenicillamine (SNAP), termed HA‐DS@PLGA. This system facilitates dual targeting of CD44‐overexpressing tumor cells and TAMs via HA‐mediated recognition while the PLGA core ensures sustained release of both agents. SNAP‐derived NO effectively attenuates DOX‐induced PD‐L1 expression through NO‐mediated signaling disruption while synergistically potentiating DOX's immunogenic cell death effects. In TAMs, the system synergistically eliminates M2 macrophages and reprograms residual macrophages toward the tumoricidal M1 phenotype via PI3K‐AKT signaling. In 4T1‐tumor‐bearing mouse models, HA‐DS@PLGA achieved 95.8%, 94.5%, and 88.4% tumor inhibition versus PBS, HA‐S@PLGA (SNAP alone), and HA‐D@PLGA (DOX alone), respectively. Meanwhile, HA‐DS@PLGA elicited systemic immunity, as evidenced by enhanced dendritic cell maturation, increased cytotoxic T lymphocyte infiltration, elevated IFN‐γ production, and downregulation of PD‐L1. By simultaneously targeting tumor‐intrinsic and microenvironment‐mediated immunosuppression, HA‐DS@PLGA overcomes multifaceted resistance mechanisms and amplifies antitumor immunity, offering a promising paradigm for combinatorial cancer nanomedicine.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Peng, X., Chen, W., Li, S., Ma, X., Dai, Y., Wang, Y., Xie, C., Xiao, Y., Han, H., Zhang, Y., & Wang, J. (2026). Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy. BMEMat. https://doi.org/10.1002/bmm2.70102

Vancouver

Peng X, Chen W, Li S, Ma X, Dai Y, Wang Y, et al. Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy. BMEMat. 2026. doi:10.1002/bmm2.70102

BibTeX
@article{Peng2026,
  author = {Peng, Xingzhou and Chen, Wei and Li, Shuyu and Ma, Xiaomin and Dai, Yanfeng and Wang, Yan and Xie, Changqiang and Xiao, Yazhe and Han, Hesong and Zhang, Yumiao and Wang, Junjie},
  title = {Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy},
  journal = {BMEMat},
  year = {2026},
  doi = {10.1002/bmm2.70102}
}
Kostenlos starten →